Interpretation of the latest progress of CDK4/6 inhibitors combining with endocrine therapy in advanced breast cancer at ASCO of 2018
10.3760/cma.j.issn.1674-6090.2019.02.015
- VernacularTitle:2018年ASCO年会CDK4/6抑制剂联合内分泌治疗晚期乳腺癌最新进展解读
- Author:
Tianhong LI
1
;
Fang GUO
;
Xiaodong XIE
Author Information
1. 辽宁中医药大学第一临床学院
- Keywords:
Advanced breast cancer,Endocrine therapy;
American Society of Clinical Oncology(ASCO)
- From:
Chinese Journal of Endocrine Surgery
2019;13(2):159-161
- CountryChina
- Language:Chinese
-
Abstract:
Endocrine therapy is the main treatment of hormone receptor-positive advanced breast cancer.How to reverse the endocrine resistance and the new endocrine therapy have become the focus of attention in the tumor community.The study of cyclin dependent kinase (CDKs) has developed rapidly,and the selective cdk4/6 inhibitors can significantly extend the progression-free survival of patients with endocrine resistance to breast cancer,which has been approved for standard treatment for advanced breast cancer.
